Although the clinical high risk for psychosis (CHR) paradigm has become well-established over the past two decades, one key component has received surprisingly little investigative attention: the predictive validity of the criteria for conversion or transition to frank psychosis. The current study evaluates the predictive validity of the transition to psychosis as measured by the Structured Interview for Psychosis-Risk Syndromes (SIPS) in CHR individuals. Participants included 33 SIPS converters and 399 CHR non-converters both from the North American Prodromal Longitudinal Study (NAPLS-2), as well as a sample of 67 separately ascertained first-episode psychosis (FEP) patients from the STEP program. Comparisons were made at baseline and one-year follow-up on demographic, diagnostic stability (SCID), and available measurement domains relating to severity of illness (psychotropic medication, psychosocial treatment, and resource utilization). Principal findings are: 1) a large majority of cases in both SIPS converters (n = 27/33, 81.8%) and FEP (n = 57/67, 85.1%) samples met criteria for continued psychosis at one-year follow-up; 2) follow-up prescription rates for current antipsychotic medication were higher in SIPS converters (n = 17/32, 53.1%) compared to SIPS non-converters (n = 81/397, 20.4%), and similar as compared to FEP cases (n = 39/65, 60%); and 3) at follow-up, SIPS converters had higher rates of resource utilization (psychiatric hospitalizations, day hospital admissions, and ER visits) than SIPS non-converters and were similar to FEP in most categories. The results suggest that the SIPS definition of psychosis onset carries substantial predictive validity. Limitations and future directions are discussed.
Keywords: Predictive validity; SIPS; Transition.
Copyright © 2019 Elsevier B.V. All rights reserved.
Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion.Version 2. Epidemiol Psychiatr Sci. 2017 Jun;26(3):287-298. doi: 10.1017/S2045796016000184. Epub 2016 Apr 8. Epidemiol Psychiatr Sci. 2017. PMID: 27056022 Free PMC article.
Course of psychotic symptoms, depression and global functioning in persons at clinical high risk of psychosis: Results of a longitudinal observation study over three years focusing on both converters and non-converters.Schizophr Res. 2017 Nov;189:19-26. doi: 10.1016/j.schres.2017.01.040. Epub 2017 Jan 28. Schizophr Res. 2017. PMID: 28139360
External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample.Psychiatry Res. 2019 Sep;279:9-14. doi: 10.1016/j.psychres.2019.06.034. Epub 2019 Jun 21. Psychiatry Res. 2019. PMID: 31279247
[Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations].Encephale. 2017 May;43(3):292-297. doi: 10.1016/j.encep.2017.01.005. Epub 2017 Mar 25. Encephale. 2017. PMID: 28347521 Review. French.
Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?Schizophr Res. 2018 Sep;199:31-38. doi: 10.1016/j.schres.2018.04.017. Epub 2018 Apr 25. Schizophr Res. 2018. PMID: 29703661 Review.
- U01 MH081902/MH/NIMH NIH HHS/United States
- P50 MH080272/MH/NIMH NIH HHS/United States
- U01 MH081988/MH/NIMH NIH HHS/United States
- P50 MH066286/MH/NIMH NIH HHS/United States
- R01 MH103831/MH/NIMH NIH HHS/United States
- K24 MH076191/MH/NIMH NIH HHS/United States
- U01 MH082022/MH/NIMH NIH HHS/United States
- U01 MH081984/MH/NIMH NIH HHS/United States
- R01 MH060720/MH/NIMH NIH HHS/United States
- U01 MH081928/MH/NIMH NIH HHS/United States
- U01 MH081857/MH/NIMH NIH HHS/United States
- U01 MH082004/MH/NIMH NIH HHS/United States
- U01 MH081944/MH/NIMH NIH HHS/United States